Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c, Revenues Beat
February 28, 2019 4:27 PM ESTSangamo Therapeutics (NASDAQ: SGMO) reported Q4 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $26.84 million versus the consensus estimate of $22.51 million.
ST-920 IND acceptance: The U.S. Food and Drug Administration (FDA) accepted the Investigational New Drug application (IND) for ST-920, a gene therapy candidate being evaluated for the treatment of adults with Fabry disease. Sangamo expects to initiate the Phase 1/2 clinical trial evaluating ST-920 later this year.WORLDSymposium presentations: At the WORLDSymposium earlier in February, Sangamo presented... More